Marc Talló-Parra
Chief Scientific Officer NoctuRNA Therapeutics
Seminars
Thursday 28th May 2026
Panel: Contrasting Circular vs. Self-Amplifying RNA to Match Modalities to Use-Cases
9:00 am
- Weigh strengths and trade-offs in potency, durability, manufacturability, and safety to guide platform decisions
- Compare fit-for-purpose advantages across CAR-T, protein replacement, combination therapies, autoimmune, and CNS applications to reduce risk
- Define where each modality delivers a strategic edge and where constraints limit applicability for smarter portfolio planning
Thursday 28th May 2026
Engineering 300-nt Circular RNAs to Unfold Pathogenic RNA Structures as a Novel Therapeutic Strategy for Infectious & NonInfectious Diseases
3:00 pm
- Reverse structure-driven pathogenicity by applying hybridization-based circRNAs that block the formation of aberrant RNA structures underlying ALS, muscular dystrophies, and viral replication
- Expand circRNA utility well beyond vaccines and protein replacement by demonstrating a new non-canonical mode of action with in vitro and in vivo proof across multiple disease classes
- Strengthen translational readiness through insights into purity thresholds, linear– circular separation, and delivery considerations unique to small, non-coding circRNA modalities
